Pfizer, BioNTech Seeks EUA from US FDA for Omicron Adapted COVID-19 Vaccine
Pfizer Inc. and BioNTech announced they have completed a submission to the US Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a booster dose of an Omicron adapted bivalent COVID-19 vaccine for individuals over 12 years. This application follows guidance from the US FDA to include clinical data from the bivalent Omicron […]
Continue Reading